The Author Replies  by Coyne, Daniel W.
The normal HCT trial re-revisited:
what were the actual findings?
To the Editor: Below is our response to the open com-
mentary1 on the Normal Hematocrit Cardiac Trial (NHCT).
K The academic coauthors of the New Engl J Med
(NEJM) report2 of the NHCT urge readers to revisit
the publication, which definitively does not recom-
mend use of epoetin to target hematocrit 42%.
Dr Coyne’s commentary in KI does not cite this
conclusion, implying that benefit occurred at higher
hematocrit.
K The commentary describes statistical reporting
‘discrepancies’, but fails to acknowledge that we
originally submitted the nominal P-value of 0.01 for
the primary end point, replaced in the manuscript
by repeated confidence intervals methodology
following NEJM editorial comment and external
statistician input.3
K The manuscript submitted to the NEJM stated, ‘There
were no statistically significant differences in quality-
of-life scores between groups or over time, using
intent-to-treat analysisy and assigning scores of zero
for patients who had died’. This sentence was deleted
by the editors, with only ‘improved physical function
scores among 12-month survivors with increases in
hematocrit’ remaining. Epoetin responders may have
different outcomes than nonresponders.
K The NEJM paper reported a statistically insignificant
higher rate of hospitalization among the target 42%
group, no different from the KI commentary in that
the adjusted risk of hospitalization was insigni-
ficantly different (P¼ 0.06).
K Aggregate non-access thrombotic events (22% vs.
18%) were added to the epoetin alfa package insert,
but were reported only by individual events in the
NEJM.
K All coauthors of the NEJM paper had full access to
the patient data and contributed to each revision.
This was the first large study to report adverse
outcomes associated with targeting normal hema-
tocrit in chronic kidney disease. There was no intent
to mislead anyone.
1. Coyne DW. The health-related quality of life was not improved by
targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int
2012; 82: 235–241.
2. Besarab A, Bolton WK, Browne JK et al. The effects of normal as
compared with low hematocrit values in patients with cardiac
disease who are receiving hemodialysis and epoetin. N Eng J Med 1998;
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The Author Replies: Despite no attempt to mislead,1 each
discrepancy favored consideration of targeting hematocrit
433%.2 One author’s subsequent commentary encouraged
hematocrit normalization, stating the trial showed ‘signiﬁcant
improvements in QOL parameters in the patients in the
normal (hematocrit) groupy’.3 We now understand the
publication merely observed that those in the high arm with
higher ‘physical function’ scores achieved higher hemato-
crit.2,4 Unstated was the fact that the low arm had just as
many patients with higher ‘physical function’ scores. Target-
ing hematocrit 433% raised no one’s quality of life. Mean
scores declined identically in both groups, and did not differ
at 12 months (P¼ 0.97).4 Guideline groups and physicians are
now better informed.
A P¼ 0.01 for all-cause death was acknowledged 11 years
after the original publication following Food and Drug
Administration (FDA) disclosure,1,2 but did not report the hazard
ratio of 1.27 and 95% conﬁdence interval of 1.04–1.54.4
I stated that the editors in 1998 agreed to publication of only
adjusted primary outcome results, and by implication the
omission of the death statistics.4
Increased hospitalizations strongly suggest higher medical
costs. Targeting normal hematocrit signiﬁcantly increased
hospitalizations in the primary predeﬁned analysis (P¼ 0.04),
and showed a trend in an adjusted predeﬁned analysis
(P¼ 0.06),4 whereas the authors in 1998 and now promote
the neutral post hoc analysis (P¼ 0.30).2 A revised FDA label,
but not the 1998 publication, reported predeﬁned thrombotic
rates (22% vs. 18%), but provided no statistical result. It was
P¼ 0.041.4
If the 1998 publication discouraged targeting hematocrit to
42%, the results indicate targeting 433% provides no beneﬁt
beyond reduced transfusions. That important difference
contributed to billions in expenditure.
1. Besarab A, Bolton WK, Nissenson AR et al. The normal HCT trial revisited:
what were the actual findings? Kidney Int 2012; 82: 242.
2. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared
with low hematocrit values in patients with cardiac disease who are
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receiving hemodialysis and epoetin (see comment). N Eng J Med 1998;
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Ischemic preconditioning and the
risk of acute kidney injury
To the Editor: We have read with interest the paper by
Zimmerman et al.,1 in which the authors randomized to
either ischemic preconditioning or no intervention 120
patients undergoing cardiac surgery. The authors reported a
marked 57% lower risk for acute kidney injury (AKI) in
patients in whom preconditioning occurred.
Such a result may be partly explained by the study being
underpowered. The authors reported that a total of 120
subjects would provide 62% power to detect a 50% reduction
in the risk of AKI. The main concern with underpowered
studies is the increased risk of type II error (failing to reject a
false null hypothesis). However, an often underlooked pro-
blem arising from underpowered studies is the increased risk
of type I error (failing to reject a true null hypothesis).2 In
particular, simulation studies have shown how studies with
low power tend to yield incorrectly inﬂated effect size estimates.3
1. Zimmerman RF, Ezeanuna PU, Kane JC et al. Ischemic preconditioning at a
remote site prevents acute kidney injury in patients following cardiac
surgery. Kidney Int 2011; 80: 861–867.
2. Christley RM. Power and error: increased risk of false positive results in
underpowered studies. Open Epid J 2010; 3: 16–19.
3. La Caze A, Duffull S. Estimating risk from underpowered, but statistically
significant, studies: was APPROVe on TARGET? J Clin Pharm Ther 2011; 36:
637–641.
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The Authors Reply: We appreciate the opportunity to
address concerns regarding statistical power in our study.1
Ferraro and Gambaro’s2 statement that underpowered studies
are at increased risk for type I error is, in our opinion, an
oversimpliﬁcation of a rather complex issue. It can be argued
that equal P-values represent equal risks for type I error
regardless of sample size, or even that lower statistical power
strengthens the evidence represented by a given P-value and
reduces the likelihood of type I error.3 As we found an effect
of remote ischemic preconditioning that was highly statisti-
cally signiﬁcant (P¼ 0.004), we consider it improbable that
ours was a ‘false-positive’ study.
The authors raise the valid point that because small,
underpowered studies require more extreme results to reach
statistical signiﬁcance, they tend to overestimate effect size.
We regret not acknowledging this issue in our discussion of
limitations. Our a priori power analysis was based on pilot
data. If the observed data in our study are ‘true’, then the
power to detect the observed differences is substantially higher
than the 62% estimated before the study started, and is rather
83%. At 60% power, the simulation studies reported by
La Caze, et al.4 indicate that the probability of signiﬁcant result
bias is quite low, and at 80% power ‘shrinks to negligible
levels’. We therefore consider it unlikely that our ﬁndings are
seriously biased vis-a`-vis the effects of low statistical power.
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Biomarker for interstitial
inflammation
To the Editor: Zhang et al.1 have conducted a proof-of-
concept cross-sectional study on biomarkers of interstitial
inﬂammation in lupus nephritis. Although the authors allude
to biomarkers leading to a ‘continuous readout of kidney
pathology’, they use a dichotomous gold standard (none–mild
vs. moderate–severe interstitial inﬂammation on histology). It
would be more informative to observe the four groups
separately as classiﬁed by the blinded nephropathologist. Was
there a gradient (dose–response) in the levels of biomarkers in
the four groups of none, mild, moderate, and severe? This
may not be ‘clinically signiﬁcant’ but will increase conﬁdence
in the result.
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